The effects of exenatide extended release ( Bydureon) on appetite and gastric emptying in Prader-Willi syndrome

Phase 3

Recruiting

• Conditions: Prader-Willi syndrome; Metabolic and Endocrine - Other endocrine disorders; Human Genetics and Inherited Disorders - Other human genetics and inherited disorders; Neurological - Other neurological disorders

• Registration Number: ACTRN12616000710426
• Lead Sponsor: Garvan Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-30
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

PWS group: genetic diagnosis of PWS
BMI-matched group( instead of Obese group): healthy; any obesity-related comorbidities must be treated, BMI -matched to PWS cohort.
Lean group: health; BMI <25

Exclusion Criteria

PWS: Uncontrolled access to food in current living situation; history of psychological illness within previous 12 months; pregnant women.
Obese: unstable body weight within previous 3 months (+/- 2kg or greater); pregnant women.
Lean: unstable body weight within previous 3 months (+/- 2kg or greater); pregnant women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified